View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Irinotecan 350, adenocarcinoma esophagogastric junction and stomach
Protocol-ID: 139 V1.1 (Mini), IRIN350, AEG/Gastric CaIndication(s)
- Gastric Cancer; ICD-10 C16.-, C16.0
- Esophageal Cancer (Adenocarcinoma Esophagogastric Junction (AEG)); ICD-10 C15.-
Links
- Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. [PMID]
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). [PMID]
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 04.07.2021